Related coverage linked through entity extraction aliases.
Jun 22, 2026
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
Jun 16, 2026
Sensei Biotherapeutics has changed its name to Faeth Therapeutics following its February 2026 acquisition of the biotechnology company. The name change accompanies a $200 million private placement financing to advance PIKTOR, an investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway in endometrial and breast cancer. Topline Phase 2 data in endometrial cancer is anticipated in the second half of 2026.
Jun 11, 2026
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Jun 01, 2026
CARsgen Therapeutics has signed a RMB370 million agreement to build a CAR T-cell manufacturing base in Shanghai, supporting commercialization of its marketed and late-stage products. Meanwhile, investment firm HarbourVest disclosed a $21 million position in CAR-T developer Generate Biomedicines, which holds $516.6 million in cash after its IPO.
May 20, 2026
A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
May 18, 2026
Regeneron and Parabilis Medicines entered a research collaboration focused on Antibody-Helicon Conjugates. The deal includes $125 million upfront and financing support and up to $2.2 billion in milestones.
May 05, 2026
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
May 01, 2026
Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
Apr 30, 2026
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.
Apr 26, 2026
Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
Apr 23, 2026
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 20, 2026
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
Apr 19, 2026
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Apr 14, 2026
Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
Apr 09, 2026
Celltrion said CT-P71 received FDA Fast Track designation for previously treated locally advanced or metastatic urothelial cancer. The ADC candidate is in Phase 1 testing.
Apr 08, 2026
Korean biotech firms will present next-generation cancer therapies at the AACR meeting, including CAR-T platforms for solid tumors, mRNA-based treatments, radiopharmaceuticals, and bispecific antibody ADCs. Companies like AbClon, Verismo Therapeutics, Hanmi Pharmaceutical, and SK Biopharmaceuticals will showcase their latest research.
Apr 03, 2026
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
Apr 02, 2026
Two innovative CAR-T approaches show promise against solid tumors in preclinical studies. An in vivo gene editing system generates CAR-T cells directly in the body, while HLA-independent T cell receptors target CD70 across various tumor types. Both methods have demonstrated tumor clearance in mouse models, potentially expanding cell therapy applications beyond blood cancers.
Apr 01, 2026
Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
